I hate to reply to my own post like someone else we all know, but I thought I'd clarify the point further. Don't forget that the data gathered from the CLIA lab will serve as AMBS's large-scale study to be used when they seek approval from the FDA. That's why the sample sizes in these recent validation studies haven't been larger -- because there will be a time for that during CLIA. At least that's how I understand it. The partner for FDA approval could be the same as CLIA or a different completely company. I always assumed GC would handle these separately, but with time frames pushed back a bit, perhaps it could be the same partner for both steps in the process just for security and a bigger bang right away. I guess we'll just have to wait and see.

I tried fighting the good fight on YMB but it's pointless. I replied to someone ripping GC today by showing him the increase in market cap from 8/13/12 (1 million) to 8/13/13 (17 million) to today (77 million). He subsequently deleted the whole thread so it wouldn't appear anymore. Thank you for starting and maintaining this board.